Immix Biopharmaincis A Clinical Stage Biopharmaceutical Company Based In The United Stateslisted On The Nasdaq Under The Ticker Immxthe Company Specializes In Developing Innovative Cell Therapiesparticularly Targeting Al Amyloidosis And Other Serious Diseases Immix Biopharma Is Pioneering Chimeric Antigen Receptor T Cellcar Ttherapieswith Its Lead Candidatenxc 201Designed To Treat Relapsed Refractory Al Amyloidosisthis Therapy Is Currently Being Evaluated In Clinical Trialsincluding The Nexicart 2 And Nexicart 1 Studiesadditionallythe Company Is Developing Imx 110 For Soft Tissue Sarcomawhich Incorporates Advancements In Tme Normalization Technology The Company Has Made Significant Progress In Its Clinical Trialswith Positive Early Results For Nxc 201Including Normalized Disease Markers In Initial Patientsthe Fda Has Granted Nxc 201 A Regenerative Medicine Advanced Therapy Designationunderscoring Its Potential To Meet Unmet Medical Needs In The Field
